Guerdjikova AI, et al. - This trial was performed to examine the efficacy of naltrexone extended-release (ER)/bupropion ER (NB) in women with major depressive disorder (MDD) and overweight/obesity for the management of weight and depressive symptoms. Outcomes suggested that NB might be effective in reducing binge eating symptoms associated with MDD and overweight/obesity. However, more likewise studies were required for the evaluation of NB in binge eating disorder (BED).

Methods

• The clinicians examined the relationship between change in self-reported binge eating behavior (evaluated with the Binge Eating Scale [BES]) and changes in weight, control of eating, and depressive symptoms.

Results

• 91% of subjects had moderate or severe BES scores, indicating BED, at baseline.
• BES scores were improved significantly from week 4, and by week 24, 83% reported “little or no problem.” 
• Improvement in BES scores associated with improvement in depressive symptoms and control of eating.